Methods for treating cancers
AssigneeGradalis, Inc.
InventorsJohn Nemunaitis, Ernest Bognar, Elyssa Sliheet, Molly Robinson, Susan Morand, Laura Nejedlik
Life of this patent
Estimating the term…
Abstract
Disclosed herein are methods for predicting the responsiveness of a cancer in a cancer patient and methods for treating the cancer by identifying the genotype of one or more genes in the patient.
Claims47
A method for predicting the responsiveness of a cancer in a cancer patient to a cancer treatment, comprising determining the genotypes of BRCA1 and/or BRCA2 in a sample from the cancer patient,
- wherein the cancer treatment comprises administering to the cancer patient an expression vector comprising:
- (a) a first insert comprising a nucleic acid sequence encoding a Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) sequence;
- and (b) a second insert comprising a sequence according to SEQ ID NO:2;
- and
- wherein a determination of one or more of the following genotypes:
- (1) BRCA1wt, (2) BRCA2 wt, and (3) BRCA1wt and BRCA2 wt, indicates that the cancer patient is responsive to the cancer treatment.
A method for predicting the responsiveness of a cancer in a cancer patient to a cancer treatment, comprising determining the genotypes of a first gene and a second gene, in a sample from the cancer patient,
- wherein the cancer treatment comprises administering to the cancer patient an expression vector comprising:
- (a) a first insert comprising a nucleic acid sequence encoding a Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) sequence;
- and (b) a second insert comprising a sequence according to SEQ ID NO:2;
- wherein the first gene is ARID1A and the second gene is selected from the group consisting of CTNNB1, MUTYH, NF1, PIK3CA, and UVSSA;
- and
- wherein a determination of one or more of the following pairs of genotypes:
- CTNNB1wt and ARID1Am, MUTYHwt and ARID1Am, NF1wt and ARID1Am, PIK3CAwt and ARID1Am, and UVSSAwt and ARID1Am, indicates that the cancer patient is responsive to the cancer treatment.
A method for treating a cancer in a cancer patient in need thereof, the method comprising administering to the cancer patient an expression vector comprising:
- a) a first insert comprising a nucleic acid sequence encoding a Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) sequence;
- and
- b) a second insert comprising a sequence according to SEQ ID NO:2, wherein the cancer patient comprises one or more of the following pairs of genotypes:
- TP53m and BRCA1wt;
- TP53m and BRCA2 wt;
- BRCA1wt and PIK3CAwt;
- BRCA1wt and NF1wt;
- BRCA1wt and ARID1Awt;
- BRCA1wt and MYCNOSwt;
- BRCA1wt and MUTYHwt;
- BRCA2 wt and PIK3CAwt;
- BRCA2 wt and NF1wt;
- BRCA2 wt and ARID1Awt;
- BRCA2 wt and MYCNOSwt;
- and BRCA2 wt and MUTYHwt.
A method for treating a cancer in a cancer patient in need thereof, the method comprising administering to the cancer patient an expression vector comprising:
- a) a first insert comprising a nucleic acid sequence encoding a Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) sequence;
- and
- b) a second insert comprising a sequence according to SEQ ID NO:2,
- wherein the cancer patient comprises one or more of the following triplets of genotypes:
- TP53m, BRCA1wt, and BRCA2 wt;
- BRCA1wt, BRCA2 wt, and PIK3CAwt;
- BRCA1wt, BRCA2 wt, and NF1wt;
- BRCA1wt, BRCA2 wt, and ARID1Awt;
- BRCA1wt, BRCA2 wt, and MYCNOSwt;
- and BRCA1wt, BRCA2 wt, and MUTYHwt.
A method for treating a cancer in a cancer patient in need thereof, the method comprising administering to the cancer patient an expression vector comprising:
- a) a first insert comprising a nucleic acid sequence encoding a Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) sequence;
- and
- b) a second insert comprising a sequence according to SEQ ID NO:2,
- wherein the cancer patient comprises one or more of the following pairs of genotypes:
- CTNNB1 wt and ARID1Am, MUTYHwt and ARID1Am, NF1 wt and ARID1Am, PIK3CAwt and ARID1Am, and UVSSAwt and ARID1Am, indicates that the cancer patient is responsive to the cancer treatment.
A method for treating a cancer in a cancer patient in need thereof, the method comprising:
- 1) genotyping the cancer patient to identify genotypes comprising BRCA1wt and/or BRCA2 wt in a sample from the cancer patient;
- 2) administering to the cancer patient an expression vector comprising:
- a) a first insert comprising a nucleic acid sequence encoding a Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) sequence;
- and
- b) a second insert comprising a sequence according to SEQ ID NO:2, to thereby treat the cancer patient.
A method for treating a cancer in a cancer patient in need thereof, the method comprising:
- 1) genotyping the cancer patient to identify one or more of the following pairs of genotypes:
- CTNNB1 wt and ARID1Am, MUTYHwt and ARID1Am, NF1 wt and ARID1Am, PIK3CAwt and ARID1Am, and UVSSAwt and ARID1Am, in a sample from the cancer patient;
- 2) administering to the cancer patient an expression vector comprising:
- a) a first insert comprising a nucleic acid sequence encoding a Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) sequence;
- and
- b) a second insert comprising a sequence according to SEQ ID NO:2, to thereby treat the cancer patient.
Dependencies are inferred from the claim text.